Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02561988
Other study ID # BLU-285-2101
Secondary ID 2015-001661-12
Status Completed
Phase Phase 1
First received
Last updated
Start date March 10, 2016
Est. completion date January 19, 2023

Study information

Verified date March 2023
Source Blueprint Medicines Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult patients with advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The study consists of 2 parts:, dose-escalation (Part 1) and expansion (Part 2).


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date January 19, 2023
Est. primary completion date October 5, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: For Part 1:Patients must have one of the following diagnoses based on World Heath Organization (WHO) diagnostic criteria: - Aggressive systemic mastocytosis (ASM). - Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) and at least 1 C-finding attributable to systemic mastocytosis (SM). The AHN must be myeloid, with the following exceptions that are excluded: Acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS) that is very high- or high-risk as defined by the International prognostic scoring system for myelodysplastic syndromes (IPSS-R) and Philadelphia chromosome positive malignancies. - Mast cell leukemia (MCL). - Histologically- or cytologically- confirmed myeloid malignancy that is relapsed or refractory to standard treatments. AML, MDS that is very high- or high-risk as defined by the IPSS-R, and Philadelphia chromosome positive malignancies are excluded. - Upon discussion with the sponsor, other relapsed or refractory, potentially avapritinib-responsive hematologic neoplasms (e.g., evidence of aberrant KIT or platelet derived growth factor receptor (PDGFR) signaling) may be considered for enrollment. For Part 2, patients must have one of the following diagnoses, based on WHO diagnostic criteria: - ASM. - SM-AHN. The AHN must be myeloid, with the following exceptions that are excluded: AML, MDS that is very high- or high-risk as defined by the IPSS-R, and Philadelphia chromosome positive malignancies. - MCL. For Part 2, Cohort 2, patients must have at least 1 measurable C-finding per modified IWG-MRT-ECNM criteria at Baseline, attributed to SM unless diagnosis is MCL, which does not require a C-finding. - Cytopenias: ANC < 1.0 × 10?/L or hemoglobin < 10 g/dL or platelet count < 75 × 10?/L. - Symptomatic ascites or pleural effusion requiring medical intervention such as: use of diuretics (Grade 2) or = 2 therapeutic paracenteses or thoracenteses (Grade 3) at least 28 days apart over the 12 weeks before study entry and 1 of the procedures is performed during the 6 weeks before study start (C1D1). - = Grade 2 abnormalities in direct bilirubin (> 1.5 × upper limit of normal [ULN]), aspartate aminotransferase (AST; > 3.0 × ULN), alanine aminotransferase (ALT; > 3.0 × ULN), or alkaline phosphatase (> 2.5 × ULN) with 1 of the following present: ascites or clinically relevant portal hypertension or liver mast cell infiltration that is biopsy-proven or no other identified cause of abnormal liver function. - = Grade 2 hypoalbuminemia (< 3.0 g/dL). - A spleen that is palpable = 5 cm below the left costal margin. - Transfusion-dependent anemia defined as: transfusion of = 6 units packed red blood cells (PRBCs) in the 12 weeks before start of treatment (C1D1) and most recent transfusion occurring during the preceding 4 weeks and transfusion administered for hemoglobin = 8.5 g/dL and reason for transfusion is not bleeding, hemolysis, or therapy-related. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3. Exclusion Criteria: - QT interval corrected using Fridericia's formula (QTcF) >480 milliseconds - Platelet count <50,000/µL (within 4 weeks of the first dose of study drug) or receiving platelet transfusion(s) - Absolute neutrophil count <500/µL - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >3 x the upper limit of normal (ULN); >5 × ULN if associated with clinically suspected liver infiltration by mastocytosis or another disease for which the patient enrolled into the study - Total bilirubin >1.5 × ULN; >3 × ULN if associated with liver infiltration by the disease being treated or in the presence of Gilbert's Disease (In the case of Gilbert's disease, a direct bilirubin > 2.0 ULN would be an exclusion.) - Estimated (Cockroft-Gault formula) or measured creatinine clearance <40 mL/min - Brain malignancy or metastases to the brain - History of a seizure disorder or requirement for anti-seizure medication - Known risk of intracranial bleeding, such as a brain aneurysm or history of subdural or subarachnoid bleeding - Eosinophilia and known positivity for the FIP1L1-PGDFRA fusion, unless the patient has demonstrated relapse or progressive disease on prior imatinib therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Avapritinib


Locations

Country Name City State
United Kingdom Beatson West of Scotland Cancer Centre Glasgow
United Kingdom Guy's Hospital London
United States University of Michigan Health System Ann Arbor Michigan
United States Emory University Atlanta Georgia
United States Dana Farber Cancer Institute Boston Massachusetts
United States University of Colorado Cancer Center Denver Colorado
United States MD Anderson Cancer Center Houston Texas
United States Mount Sinai Hospital New York New York
United States University of Pennsylvania Philadelphia Pennsylvania
United States Huntsman Cancer Institute Salt Lake City Utah
United States Stanford Cancer Institute Stanford California

Sponsors (1)

Lead Sponsor Collaborator
Blueprint Medicines Corporation

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) of avapritinib (also known as BLU-285) During cycle 1 (28 days) of treatment
Primary Number of patients with adverse and serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findings Approximately 24 months
Primary Recommended Phase 2 dose (RP2D) of avapritinib Approximately 24 months
Secondary Maximum plasma concentration of avapritinib Blood samples may be taken at pre-dose, and 0.5, 1, 2, 4, 8 and 24 hrs post dose (plus 10 and 48 hrs post dose in Part 2) on Cycle 1 Day 1 and Cycle 1 Day 15, Pre-dose of Cycle 2 to 4, Day 1 Every cycle (28 days) up to cycle 4
Secondary Time to maximum plasma concentration of avapritinib Blood samples may be taken at pre-dose, and 0.5, 1, 2, 4, 8 and 24 hrs post dose (plus 10 and 48 hrs post dose in Part 2) on Cycle 1 Day 1 and Cycle 1 Day 15, Pre-dose of Cycle 2 to 4, Day 1 Every cycle (28 days) up to cycle 4
Secondary Overall Response Rate Including complete remission (CR), CR with partial recovery of peripheral blood (CRh), partial remission (PR) and clinical improvement (CI) using modified International Working Group Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European competence network on mastocytosis (ECNM) criteria; and duration of response (DOR) 8, 24, 40, 68 and every 24 weeks until patient terminates from the study (approximately 24 months)
Secondary Morphologic response Including morphologic complete remission (mCR), morphologic CR with partial recovery of peripheral blood (mCRh), and morphologic partial remission (mPR) based on Pure Pathologic Response = 12 weeks
Secondary Changes in levels of serum tryptase and levels of V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) D816V allele burden in blood Cycle (C)1Day (D)1, C1D15, C2D1, C3D1, C5D1, C7D1, C11D1, C18D1 every 6 cycles thereafter and at disease progression. (approximately 24 months)
Secondary Changes in patient reported symptoms and quality of life using the Patient Global Impression of Symptom Severity (PGIS) scale Defined as change from Baseline Part 2 only - Day 1 of Cycles 1-12
Secondary Changes in patient reported quality of life using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C-30) Defined as change from Baseline Part 2 only - Day 1 of Cycles 1-12
Secondary Changes in patient reported outcomes using the advanced SM symptom assessment form (AdvSM-SAF) Defined as change from Baseline Part 2 only - daily from Day -7 through Cycle 12
Secondary Change in liver volume by imaging mL Day 1 of Cycles 5-18, and every 6 cycles thereafter (each cycle is 28 days)
Secondary Change in spleen volume by imaging mL Day 1 of Cycles 5-18, and every 6 cycles thereafter (each cycle is 28 days)
See also
  Status Clinical Trial Phase
Completed NCT01807598 - Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Phase 2
Terminated NCT00387426 - Sunitinib in Treating Patients With Idiopathic Myelofibrosis Phase 2
Completed NCT00898079 - Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Active, not recruiting NCT03580655 - (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Phase 2
Completed NCT00112593 - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer N/A
Completed NCT00006251 - Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Phase 1/Phase 2
Terminated NCT02415608 - Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Phase 2
Active, not recruiting NCT00118352 - Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Phase 2
Completed NCT01869777 - Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia N/A
Completed NCT01273766 - Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Phase 2
Completed NCT01231919 - MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Phase 1
Terminated NCT03214666 - GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies Phase 1/Phase 2
Completed NCT01199562 - Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Completed NCT00014235 - Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies N/A
Completed NCT04695431 - Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
Completed NCT00890747 - Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Phase 1
Completed NCT01053494 - Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer N/A
Available NCT05219266 - Managed Access Programs for PKC412, Midostaurin